NASDAQ:ADXS Ayala Pharmaceuticals (ADXS) Stock Price, News & Analysis → The Hard Truth About Investing For Retirement (From Insiders Exposed) (Ad) Free ADXS Stock Alerts $0.55 +0.01 (+1.85%) (As of 04/25/2024 ET) Add Compare Share Share Today's Range$0.55▼$0.5550-Day Range$0.54▼$0.9752-Week Range$0.50▼$1.95Volume426 shsAverage Volume20,557 shsMarket Capitalization$5.91 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsSocial Media Get Ayala Pharmaceuticals alerts: Email Address Ad TranzactWhat is Medicare Supplement Insurance?Original Medicare helps covers a lot of hospital and medical services, but it still leaves some out- of- pocket medical costs to recipients. Make sure your family’s nest egg is protected from unpredictable medical expenses. Consider applying for a Medicare Supplement Insurance Plan that travels with you. Learn More Here About Ayala Pharmaceuticals Stock (NASDAQ:ADXS)Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia. Ayala Pharmaceuticals, Inc. is based in Wilmington, Delaware.Read More ADXS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ADXS Stock News HeadlinesApril 24, 2024 | americanbankingnews.comAyala Pharmaceuticals (NASDAQ:ADXS) Research Coverage Started at StockNews.comApril 16, 2024 | americanbankingnews.comStockNews.com Initiates Coverage on Ayala Pharmaceuticals (NASDAQ:ADXS)April 25, 2024 | Stansberry Research (Ad)World’s biggest multibillionaire investor is buying THIS by the ton [picture]Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.April 2, 2024 | seekingalpha.comImmunome: An Oncology Powerhouse In The MakingMarch 26, 2024 | globenewswire.comAyala Pharmaceuticals Announces Completion of Sale of AL102 to ImmunomeMarch 16, 2024 | finance.yahoo.comIMNM Oct 2024 22.500 callMarch 16, 2024 | finance.yahoo.comIMNM Oct 2024 25.000 callMarch 16, 2024 | finance.yahoo.comIMNM Oct 2024 25.000 putApril 25, 2024 | Stansberry Research (Ad)World’s biggest multibillionaire investor is buying THIS by the ton [picture]Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.March 16, 2024 | finance.yahoo.comIMNM Oct 2024 45.000 callFebruary 20, 2024 | businesswire.comImmunome Recognizes Ayala Pharmaceuticals' Announced Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid TumorsFebruary 10, 2024 | msn.comAdvaxis Executes Strategic Unregistered Equity SalesFebruary 7, 2024 | msn.comAdvaxis Announces Definitive Agreement with Ayala PharmaceuticalsFebruary 6, 2024 | msn.comImmunome to buy AL102, a phase 3 asset for treatment of desmoid tumorsFebruary 6, 2024 | finance.yahoo.comImmunome to Acquire AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala PharmaceuticalsNovember 24, 2023 | morningstar.comAyala Pharmaceuticals Inc Ordinary Shares ADXSNovember 20, 2023 | sfgate.comAyala Pharmaceuticals: Fiscal Q4 Earnings SnapshotNovember 17, 2023 | msn.comLadenburg Thalmann Downgrades Ayala Pharmaceuticals (ADXS)October 23, 2023 | finance.yahoo.comAyala Pharmaceuticals Presents Updated AL102 Results from Phase 2 Clinical Trial in Desmoid Tumors at ESMO Congress 2023October 19, 2023 | finance.yahoo.comAyala Pharmaceuticals Announces Closing of Merger with BiosightAugust 10, 2023 | finance.yahoo.comAyala Pharmaceuticals Announces Second Quarter 2023 Financial Results and Provides Corporate UpdateAugust 3, 2023 | investing.comAyala Pharmaceuticals Inc (ADXS)August 1, 2023 | finance.yahoo.comAyala Pharmaceuticals Announces Abstracts on AL102 and AL101 Accepted for Presentation at ESMO Congress 2023July 27, 2023 | finance.yahoo.comAyala Pharmaceuticals and Biosight Enter into Definitive Merger AgreementJuly 5, 2023 | finance.yahoo.comAyala Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA Regarding AL102 for the Treatment of Desmoid TumorsJune 5, 2023 | finance.yahoo.comUpdated RINGSIDE Phase 2 Results Featured in Poster Discussion Session at 2023 American Society of Clinical Oncology (ASCO) Annual MeetingMay 25, 2023 | finance.yahoo.comAyala Pharmaceuticals Announces Updated RINGSIDE Phase 2 Results at 2023 American Society of Clinical Oncology (ASCO) Annual MeetingSee More Headlines Receive ADXS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ayala Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings9/09/2021Today4/25/2024Next Earnings (Estimated)5/21/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ADXS CUSIPN/A CIK1100397 Webwww.ayalapharma.com Phone609-452-9813Fax609-452-9818EmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)($7.98) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-48,070,000.00 Net MarginsN/A Pretax Margin-399,876.94% Return on Equity-3,967.23% Return on Assets-339.10% Debt Debt-to-Equity RatioN/A Current Ratio0.30 Quick Ratio0.30 Sales & Book Value Annual Sales$10,000.00 Price / Sales591.25 Cash FlowN/A Price / Cash FlowN/A Book Value($2.27) per share Price / Book-0.24Miscellaneous Outstanding Shares10,750,000Free Float10,684,000Market Cap$5.91 million OptionableNot Optionable Beta1.62 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesDr. Ruth Ben Yakar Ph.D. (Age 54)Chief Exec. Officer Dr. Stela Gangrenovitch Ph.D.Co-Founder, Chief Scientist Officer and DirectorMr. Mark Gengrinovitch LLBCo-Founder, Chief Financial Officer and DirectorKey CompetitorsHoth TherapeuticsNASDAQ:HOTHXenetic BiosciencesNASDAQ:XBIOSonnet BioTherapeuticsNASDAQ:SONNFirst Wave BioPharmaNASDAQ:FWBIVaccinexNASDAQ:VCNXView All Competitors ADXS Stock Analysis - Frequently Asked Questions Should I buy or sell Ayala Pharmaceuticals stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Ayala Pharmaceuticals in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ADXS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ADXS, but not buy additional shares or sell existing shares. View ADXS analyst ratings or view top-rated stocks. How have ADXS shares performed in 2024? Ayala Pharmaceuticals' stock was trading at $0.6670 at the beginning of 2024. Since then, ADXS stock has decreased by 17.5% and is now trading at $0.55. View the best growth stocks for 2024 here. When is Ayala Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 21st 2024. View our ADXS earnings forecast. How were Ayala Pharmaceuticals' earnings last quarter? Ayala Pharmaceuticals, Inc. (NASDAQ:ADXS) issued its quarterly earnings data on Thursday, September, 9th. The company reported ($0.02) EPS for the quarter, topping analysts' consensus estimates of ($0.04) by $0.02. The company earned $0.25 million during the quarter. What other stocks do shareholders of Ayala Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Ayala Pharmaceuticals investors own include Inovio Pharmaceuticals (INO), Madrigal Pharmaceuticals (MDGL), Merck & Co., Inc. (MRK), Anavex Life Sciences (AVXL), Vistagen Therapeutics (VTGN), Novavax (NVAX), Highpower International (HPJ), OPKO Health (OPK) and Athersys (ATHX). How do I buy shares of Ayala Pharmaceuticals? Shares of ADXS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ADXS) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsGlobal crypto currency reset (41 major banks signed up)Stansberry ResearchThe only accurate crypto trading system I know …Weiss RatingsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ayala Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.